{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:24Z","timestamp":1791920904972,"version":"4.3.4"},"reference-count":21,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Egyptian Government","award":["Channel Scholarship Scheme"],"award-info":[{"award-number":["Channel Scholarship Scheme"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The Bcl-2 protein has been studied as an anticancer drug target in recent years, due to its gatekeeper role in resisting programmed cancer cell death (apoptosis), and the design of BH3 domain mimetics has led to the clinical approval of Venetoclax (ABT-199) for the treatment of chronic lymphocytic leukaemia. In this work we extend our previous studies on the discovery of indole-based heterocycles as Bcl-2 inhibitors, to the identification of quinolin-4-yl based oxadiazole and triazole analogues. Target compounds were readily synthesized via a common aryl-substituted quinolin-4-carbonyl-N-arylhydrazine-1-carbothioamide (5a\u2013b) intermediate, through simple variation of the basic cyclisation conditions. Some of the quinoline-based oxadiazole analogues (e.g. compound 6i) were found to exhibit sub-micromolar anti-proliferative activity in Bcl-2-expressing cancer cell lines, and sub-micromolar IC50 activity within a Bcl2-Bim peptide ELISA assay. The Bcl-2 targeted anticancer activity of 6i was further rationalised via computational molecular modelling, offering possibilities to extend this work into the design of further potent and selective Bcl-2 inhibitory heteroaromatics with therapeutic potential.<\/jats:p>","DOI":"10.3390\/molecules24071274","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T03:39:28Z","timestamp":1554262768000},"page":"1274","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2"],"prefix":"10.3390","volume":"24","author":[{"given":"Rania","family":"Hamdy","sequence":"first","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, Wales CF10 3NB, UK"},{"name":"Sharjah Institute for Medical Research, College of Pharmacy, University of Sharjah, P.O. Box 27272, Sharjah, UAE"},{"name":"Faculty of Pharmacy, Zagazig University, Zagazig 445519, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia A.","family":"Elseginy","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, Wales CF10 3NB, UK"},{"name":"Green Chemistry Department, Chemical Industries Research Division, National Research Center, Dokki, Giza, P.O. Box 12622, Egypt"},{"name":"School of Biochemistry, University of Bristol, University Walk, Bristol BS8 1TD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha I.","family":"Ziedan","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, Wales CF10 3NB, UK"},{"name":"Faculty of Pharmacy, Zagazig University, Zagazig 445519, Egypt"},{"name":"Department of Natural Sciences, University of Chester, Chester CH2 4NU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwyn T.","family":"Jones","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, Wales CF10 3NB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5166-9236","authenticated-orcid":false,"given":"Andrew D.","family":"Westwell","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, Wales CF10 3NB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: Next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2174\/138955708784567430","article-title":"The development of pro-apoptotic cancer therapeutics","volume":"8","author":"Ziedan","year":"2008","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2018-02-791350","article-title":"The rise of apoptosis: Targeting apoptosis in hematological malignancies","volume":"132","author":"Valentin","year":"2018","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.bmcl.2013.02.029","article-title":"Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents","volume":"23","author":"Hamdy","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.bmcl.2016.12.061","article-title":"Synthesis and evaluation of 5-(1H-indol-3-yl)-N-aryl-1,3,4-oxadiazol-2-amines as Bcl-2 inhibitory anticancer agents","volume":"27","author":"Hamdy","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cbdd.12936","article-title":"Virtual screening, SAR, and discovery of 5-(indol-3-yl)-2-[(2-nitrophenyl)amino][1,3,4]-oxadiazoles as a novel Bcl-2 inhibitor","volume":"90","author":"Ziedan","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/B:COHC.0000028623.41308.e5","article-title":"The Pfitzinger reaction (review)","volume":"40","author":"Shvekhgeimer","year":"2004","journal-title":"Chem. Heterocycl. Cpds."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1016\/j.tetlet.2006.05.033","article-title":"Synthesis of 2-amino-5-substituted-1,3,4-oxadiazoles using 1,3-dibromo-5,5-dimethylhydantoin as oxidant","volume":"47","author":"Rivera","year":"2006","journal-title":"Tetrahedron Lett."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/jhet.1738","article-title":"Synthesis and antimicrobial activity of new derivatives of 1,3,4-thiadiazoles and 1,2,4-triazoles with 5-nitroindazole as support","volume":"50","author":"Cheptea","year":"2013","journal-title":"J. Heterocycl. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.3390\/molecules14072621","article-title":"Synthesis and biological activity of some 1,3,4-thiadiazole and 1,2,4-triazole compounds containing a phenylalanine moiety","volume":"14","author":"Moise","year":"2009","journal-title":"Molecules"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.bmc.2005.11.029","article-title":"Design, synthesis, and biological evaluation of substituted 3-alkylthio-4,5-diaryl-4H-1,2,4-triazoles as selective COX-2 inhibitors","volume":"14","author":"Navidpour","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1038\/sj.onc.1202650","article-title":"Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein","volume":"18","author":"Li","year":"1999","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s002800050767","article-title":"Expression of Bcl-2 in human epithelial tumor (HeLa) cells enhances clonogenic survival following exposure to 5-fluoro-2\u2019-deoxyuridine or staurosporine, but not following exposure to etoposide or doxorubicin","volume":"41","author":"Elliott","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/mt.2011.175","article-title":"Co-operative membrane disruption between cell-penetrating peptide and cargo: Implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8","volume":"19","author":"Watkins","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1479-5876-9-71","article-title":"Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34(+) acute myeloid leukemia cell lines and primary sorted CD34(+) acute myeloid leukemia cells","volume":"9","author":"Rao","year":"2011","journal-title":"J. Trans Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1158\/1535-7163.MCT-08-0333","article-title":"Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa","volume":"7","author":"Meng","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_18","unstructured":"(2018, July 10). Chemical Computing Group - Molecular Operating Environment. Available online: https:\/\/www.chemcomp.com\/MOE-Molecular_Operating_Environment.htm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1016\/j.bmcl.2012.04.103","article-title":"Identification of a phenylacylsulfonamide series of dual Bcl-2\/Bcl-XL antogonists","volume":"22","author":"Perez","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.1021\/acs.jmedchem.7b01862","article-title":"Design, synthesis and biological evaluation of 4-quinoline carboxylic acids as inhibitors of dihydroorotate dehydrogenase","volume":"61","author":"Madak","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bioorg.2014.12.003","article-title":"Synthesis, molecular docking and anti-inflammatory screening of novel quinolone incorporated pyrazole derivatives using the Pfitzinger reaction II","volume":"58","author":"Osman","year":"2015","journal-title":"Bioorg. Chem."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/7\/1274\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:42:14Z","timestamp":1760186534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/7\/1274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["molecules24071274"],"URL":"https:\/\/doi.org\/10.3390\/molecules24071274","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,2]]}}}